ZNTL catalysts
Catalysts and events linked to ZNTL, newest first.
ZNTL stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian Candidate 2026-10-19 · Up | biomarker validation and Phase 3 clinical de-risking for azenosertib | DENALI Part 1b abstract shows 15.8-month median OS in Cyclin E1-positive vs 7.5 months in negative. | Not recorded |
| Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO 2026-10-19 · Up | biomarker clinical survival de-risking registrational trial path | DENALI Part 1b interim OS reached 15.8 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients. | Not recorded |
| Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026 2026-10-19 · Up | biomarker validation extending median overall survival to 15.8 months | DENALI Part 1b abstract showed 15.8 months median OS in Cyclin E1-positive ovarian cancer versus 7.5 months in negatives. | Not recorded |
| Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress 2026-10-19 · Up | clinical derisking of lead asset pipeline via statistically superior overall survival readout | ESMO abstract confirmed 15.8-month median OS for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer. | Not recorded |
Do these developments change your position?
Review ZNTL alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMOZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMOZNTL
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.